Cephalosporins: A Focus on Side Chains and β-Lactam Cross-Reactivity

Saira B Chaudhry, Michael P Veve, Jamie L Wagner, Saira B Chaudhry, Michael P Veve, Jamie L Wagner

Abstract

Cephalosporins are among the most commonly prescribed antibiotic classes due to their wide clinical utility and general tolerability, with approximately 1-3% of the population reporting a cephalosporin allergy. However, clinicians may avoid the use of cephalosporins in patients with reported penicillin allergies despite the low potential for cross-reactivity. The misdiagnosis of β-lactam allergies and misunderstanding of cross-reactivity among β-lactams, including within the cephalosporin class, often leads to use of broader spectrum antibiotics with poor safety and efficacy profiles and represents a serious obstacle for antimicrobial stewardship. Risk factors for cephalosporin allergies are broad and include female sex, advanced age, and a history of another antibiotic or penicillin allergy; however, cephalosporins are readily tolerated even among individuals with true immediate-type allergies to penicillins. Cephalosporin cross-reactivity potential is related to the structural R1 side chain, and clinicians should be cognizant of R1 side chain similarities when prescribing alternate β-lactams in allergic individuals or when new cephalosporins are brought to market. Clinicians should consider the low likelihood of true cephalosporin allergy when clinically indicated. The purpose of this review is to provide an overview of the role of cephalosporins in clinical practice, and to highlight the incidence of, risk factors for, and cross-reactivity of cephalosporins with other antibiotics.

Keywords: beta-lactam allergy; cephalosporin; cross-reactivity; side chain.

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Structural similarities between penicillins, cephalosporins, carbapenems, monobactams, and common β-lactam ring. R1 side chains are depicted in red; R2 side chains are depicted in blue.

References

    1. Macy E., Poon K.Y.T. Self-reported antibiotic allergy incidence and prevalence: Age and sex effects. Am. J. Med. 2009;122:778.e1–778.e7. doi: 10.1016/j.amjmed.2009.01.034.
    1. Kelkar P.S., Li J.T. Cephalosporin allergy. N. Engl. J. Med. 2001;345:804–809. doi: 10.1056/NEJMra993637.
    1. Yuson C., Kumar K., Le A., Ahmadie A., Banovic T., Heddle R., Kette F., Smith W., Hissaria P. Immediate Cephalosporin Allergy. Intern. Med. J. 2019 doi: 10.1111/imj.14229.
    1. Pichichero M., Casey J. Comparison of European and U.S. results for cephalosporin versus penicillin treatment of group A streptococcal tonsillopharyngitis. Eur. J. Clin. Microbiol. Infect. Dis. 2006;25:354–364. doi: 10.1007/s10096-006-0154-7.
    1. MacFadden D.R., LaDelfa A., Leen J., Gold W.L., Daneman N., Weber E., Al-Busaidi I., Petrescu D., Saltzman I., Devlin M., et al. Impact of Reported Beta-Lactam Allergy on Inpatient Outcomes: A Multicenter Prospective Cohort Study. Clin. Infect. Dis. 2016;63:904–910. doi: 10.1093/cid/ciw462.
    1. Joint Task Force on Practice Parameters. American Academy of Allergy. Asthma and Immunology. the American College of Allergy. Asthma and Immunology. and the Joint Council of Allergy. Asthma and Immunology Drug allergy: An updated practice parameter. Ann. Allergy Asthma Immunol. 2010;105:259–273. doi: 10.1016/j.anai.2010.08.002.
    1. Sakoulas G., Geriak M., Nizet V. Is a Reported Penicillin Allergy Sufficient Grounds to Forgo the Multidimensional Antimicrobial Benefits of beta-Lactam Antibiotics? Clin. Infect. Dis. 2019;68:157–164. doi: 10.1093/cid/ciy557.
    1. Lee C.E., Zembower T.R., Fotis M.A., Postelnick M.J., Greenberger P.A., Peterson L.R., Noskin G.A. The incidence of antimicrobial allergies in hospitalized patients: Implications regarding prescribing patterns and emerging bacterial resistance. Arch. Intern. Med. 2000;160:2819–2822. doi: 10.1001/archinte.160.18.2819.
    1. Pilzer J.D., Burke T.G., Mutnick A.H. Drug allergy assessment at a university hospital and clinic. Am. J. Health Syst. Pharm. 1996;53:2970–2975. doi: 10.1093/ajhp/53.24.2970.
    1. Blumenthal K.G., Parker R.A., Shenoy E.S., Walensky R.P. Improving Clinical Outcomes in Patients with Methicillin-Sensitive Staphylococcus aureus Bacteremia and Reported Penicillin Allergy. Clin. Infect. Dis. 2015;61:741–749. doi: 10.1093/cid/civ394.
    1. Blumenthal K.G., Shenoy E.S., Huang M., Kuhlen J.L., Ware W.A., Parker R.A., Walensky R.P. The Impact of Reporting a Prior Penicillin Allergy on the Treatment of Methicillin-Sensitive Staphylococcus aureus Bacteremia. PLoS ONE. 2016;11:e0159406. doi: 10.1371/journal.pone.0159406.
    1. Macy E., Contreras R. Health care use and serious infection prevalence associated with penicillin “allergy” in hospitalized patients: A cohort study. J. Allergy Clin. Immunol. 2014;133:790–796. doi: 10.1016/j.jaci.2013.09.021.
    1. Charneski L., Deshpande G., Smith S.W. Impact of an antimicrobial allergy label in the medical record on clinical outcomes in hospitalized patients. Pharmacotherapy. 2011;31:742–747. doi: 10.1592/phco.31.8.742.
    1. Jeffres M.N., Narayanan P.P., Shuster J.E., Schramm G.E. Consequences of avoiding beta-lactams in patients with beta-lactam allergies. J. Allergy Clin. Immunol. 2016;137:1148–1153. doi: 10.1016/j.jaci.2015.10.026.
    1. Veve M.P., January S.E., Kenney R.M., Zoratti E.M., Zervos M.J., Davis S.L. Impact of Reported beta-Lactam Allergy on Management of Methicillin-Sensitive Staphylococcus aureus Bloodstream Infections. J. Pharm. Pract. 2019 doi: 10.1177/0897190019841737.
    1. Yuson C.L., Katelaris C.H., Smith W.B. ‘Cephalosporin allergy’ label is misleading. Aust. Prescr. 2018;41:37–41. doi: 10.18773/austprescr.2018.008.
    1. Zagursky R.J., Pichichero M.E. Cross-reactivity in beta-Lactam Allergy. J. Allergy Clin. Immunol. Pract. 2018;6:72–81. doi: 10.1016/j.jaip.2017.08.027.
    1. MacDougall C. Penicillins, Cephalosporins, and Other β-Lactam Antibiotics. In: Brunton L.L., Hilal-Dandan R., Knollmann B.C., editors. Goodman & Gilman’s: The Pharmacological Basis of Therapeutics, 13e. McGraw-Hill Education; New York, NY, USA: 2017.
    1. Bratzler D.W., Dellinger E.P., Olsen K.M., Perl T.M., Auwaerter P.G., Bolon M.K., Fish D.N., Napolitano L.M., Sawyer R.G., Slain D., et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am. J. Health Syst. Pharm. 2013;70:195–283. doi: 10.2146/ajhp120568.
    1. Mackeen A.D., Packard R.E., Ota E., Speer L. Antibiotic regimens for postpartum endometritis. Cochrane Database Syst. Rev. 2015 doi: 10.1002/14651858.CD001067.pub3.
    1. Kusumoto F.M., Schoenfeld M.H., Wilkoff B.L., Berul C.I., Birgersdotter-Green U.M., Carrillo R., Cha Y.M., Clancy J., Deharo J.C., Ellenbogen K.A., et al. 2017 HRS expert consensus statement on cardiovascular implantable electronic device lead management and extraction. Heart Rhythm. 2017;14:e503–e551. doi: 10.1016/j.hrthm.2017.09.001.
    1. Shulman S.T., Bisno A.L., Clegg H.W., Gerber M.A., Kaplan E.L., Lee G., Martin J.M., Van Beneden C. Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 2012;55:1279–1282. doi: 10.1093/cid/cis847.
    1. Lipsky B.A., Berendt A.R., Cornia P.B., Pile J.C., Peters E.J., Armstrong D.G., Deery H.G., Embil J.M., Joseph W.S., Karchmer A.W., et al. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin. Infect. Dis. 2012;54:e132–e173. doi: 10.1093/cid/cis346.
    1. Solomkin J.S., Mazuski J.E., Bradley J.S., Rodvold K.A., Goldstein E.J., Baron E.J., O’Neill P.J., Chow A.W., Dellinger E.P., Eachempati S.R., et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin. Infect. Dis. 2010;50:133–164. doi: 10.1086/649554.
    1. Hospenthal D.R., Murray C.K., Andersen R.C., Bell R.B., Calhoun J.H., Cancio L.C., Cho J.M., Chung K.K., Clasper J.C., Colyer M.H., et al. Guidelines for the prevention of infections associated with combat-related injuries: 2011 update: Endorsed by the Infectious Diseases Society of America and the Surgical Infection Society. J. Trauma. 2011;71:S210–S234. doi: 10.1097/TA.0b013e318227ac4b.
    1. Osmon D.R., Berbari E.F., Berendt A.R., Lew D., Zimmerli W., Steckelberg J.M., Rao N., Hanssen A., Wilson W.R., Infectious Diseases Society of America Diagnosis and management of prosthetic joint infection: Clinical practice guidelines by the Infectious Diseases Society of America. Clin. Infect. Dis. 2013;56:e1–e25. doi: 10.1093/cid/cis803.
    1. Gupta K., Hooton T.M., Naber K.G., Wullt B., Colgan R., Miller L.G., Moran G.J., Nicolle L.E., Raz R., Schaeffer A.J., et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin. Infect. Dis. 2011;52:e103–e120. doi: 10.1093/cid/ciq257.
    1. Wilson W., Taubert K.A., Gewitz M., Lockhart P.B., Baddour L.M., Levison M., Bolger A., Cabell C.H., Takahashi M., Baltimore R.S., et al. Prevention of infective endocarditis: Guidelines from the American Heart Association: A guideline from the American Heart Association Rheumatic Fever, Endocarditis and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. J. Am. Dent. Assoc. 2007;138:1736–1754.
    1. Berbari E.F., Kanj S.S., Kowalski T.J., Darouiche R.O., Widmer A.F., Schmitt S.K., Hendershot E.F., Holtom P.D., Huddleston P.M., 3rd, Petermann G.W., et al. 2015 Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for the Diagnosis and Treatment of Native Vertebral Osteomyelitis in Adults. Clin. Infect. Dis. 2015;61:e26–e46. doi: 10.1093/cid/civ482.
    1. Nicolle L.E., Gupta K., Bradley S.F., Colgan R., DeMuri G.P., Drekonja D., Eckert L.O., Geerlings S.E., Koves B., Hooton T.M., et al. Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of Americaa. Clin. Infect. Dis. 2019 doi: 10.1093/cid/ciz021.
    1. Stevens D.L., Bisno A.L., Chambers H.F., Dellinger E.P., Goldstein E.J., Gorbach S.L., Hirschmann J.V., Kaplan S.L., Montoya J.G., Wade J.C., et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 2014;59:e10–e52. doi: 10.1093/cid/ciu296.
    1. O’Grady N.P., Alexander M., Burns L.A., Dellinger E.P., Garland J., Heard S.O., Lipsett P.A., Masur H., Mermel L.A., Pearson M.L., et al. Summary of recommendations: Guidelines for the Prevention of Intravascular Catheter-related Infections. Clin. Infect. Dis. 2011;52:1087–1099. doi: 10.1093/cid/cir138.
    1. Zacharioudakis I.M., Zervou F.N., Arvanitis M., Ziakas P.D., Mermel L.A., Mylonakis E. Antimicrobial lock solutions as a method to prevent central line-associated bloodstream infections: A meta-analysis of randomized controlled trials. Clin. Infect. Dis. 2014;59:1741–1749. doi: 10.1093/cid/ciu671.
    1. McDanel J.S., Roghmann M.C., Perencevich E.N., Ohl M.E., Goto M., Livorsi D.J., Jones M., Albertson J.P., Nair R., O’Shea A.M.J., et al. Comparative Effectiveness of Cefazolin Versus Nafcillin or Oxacillin for Treatment of Methicillin-Susceptible Staphylococcus aureus Infections Complicated by Bacteremia: A Nationwide Cohort Study. Clin. Infect. Dis. 2017;65:100–106. doi: 10.1093/cid/cix287.
    1. Eljaaly K., Alshehri S., Erstad B.L. Systematic Review and Meta-analysis of the Safety of Antistaphylococcal Penicillins Compared to Cefazolin. Antimicrob. Agents Chemother. 2018;62 doi: 10.1128/AAC.01816-17.
    1. Baddour L.M., Wilson W.R., Bayer A.S., Fowler V.G., Jr., Tleyjeh I.M., Rybak M.J., Barsic B., Lockhart P.B., Gewitz M.H., Levison M.E., et al. Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association. Circulation. 2015;132:1435–1486. doi: 10.1161/CIR.0000000000000296.
    1. Workowski K.A., Bolan G.A. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2015. MMWR Recomm. Rep. 2015;64:1–137.
    1. Wormser G.P., Dattwyler R.J., Shapiro E.D., Halperin J.J., Steere A.C., Klempner M.S., Krause P.J., Bakken J.S., Strle F., Stanek G., et al. The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: Clinical practice guidelines by the Infectious Diseases Society of America. Clin. Infect. Dis. 2006;43:1089–1134. doi: 10.1086/508667.
    1. Sagent Pharmaceuticals . Cefoxitin [Package Insert] Sagent Pharmaceuticals; Schaumburg, IL, USA: 2018.
    1. Mandell L.A., Wunderink R.G., Anzueto A., Bartlett J.G., Campbell G.D., Dean N.C., Dowell S.F., File T.M., Jr., Musher D.M., Niederman M.S., et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin. Infect. Dis. 2007;44(Suppl. 2):S27–S72. doi: 10.1086/511159.
    1. Halperin J.J., Shapiro E.D., Logigian E., Belman A.L., Dotevall L., Wormser G.P., Krupp L., Gronseth G., Bever C.T., Jr., Quality Standards Subcommittee of the American Academy of Neurology Practice parameter: Treatment of nervous system Lyme disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2007;69:91–102. doi: 10.1212/01.wnl.0000265517.66976.28.
    1. Livermore D.M. beta-Lactamases in laboratory and clinical resistance. Clin. Microbiol. Rev. 1995;8:557–584. doi: 10.1128/CMR.8.4.557.
    1. Runyon B.A., ASSLD Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. Hepatology. 2013;57:1651–1653. doi: 10.1002/hep.26359.
    1. Taplitz R.A., Kennedy E.B., Bow E.J., Crews J., Gleason C., Hawley D.K., Langston A.A., Nastoupil L.J., Rajotte M., Rolston K.V., et al. Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update. J. Clin. Oncol. 2018;36:3043–3054. doi: 10.1200/JCO.18.00374.
    1. Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents: Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. [(accessed on 15 May 2019)]; Last Updated 15 October 2018. Available online: .
    1. DePestel D.D., Benninger M.S., Danziger L., LaPlante K.L., May C., Luskin A., Pichichero M., Hadley J.A. Cephalosporin use in treatment of patients with penicillin allergies. J. Am. Pharm. Assoc. 2008;48:530–540. doi: 10.1331/JAPhA.2008.07006.
    1. Tunkel A.R., Glaser C.A., Bloch K.C., Sejvar J.J., Marra C.M., Roos K.L., Hartman B.J., Kaplan S.L., Scheld W.M., Whitley R.J., et al. The management of encephalitis: Clinical practice guidelines by the Infectious Diseases Society of America. Clin. Infect. Dis. 2008;47:303–327. doi: 10.1086/589747.
    1. Teligent Pharmac, Inc. Ceftazidime [Package Insert] Teligent Pharmac, Inc.; Buena, NJ, USA: 2017.
    1. Freifeld A.G., Bow E.J., Sepkowitz K.A., Boeckh M.J., Ito J.I., Mullen C.A., Raad I.I., Rolston K.V., Young J.A., Wingard J.R., et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin. Infect. Dis. 2011;52:e56–e93. doi: 10.1093/cid/cir073.
    1. Kalil A.C., Metersky M.L., Klompas M., Muscedere J., Sweeney D.A., Palmer L.B., Napolitano L.M., O’Grady N.P., Bartlett J.G., Carratala J., et al. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin. Infect. Dis. 2016;63:e61–e111. doi: 10.1093/cid/ciw353.
    1. Sanofi-Aventis . Cefotaxime [Package Insert] Sanofi-Aventis; Bridgewater, NJ, USA: 2014.
    1. Pfizer Inc. Cefoperazone [Package Insert] Pfizer Inc.; New York, NY, USA: 2015.
    1. Shane A.L., Mody R.K., Crump J.A., Tarr P.I., Steiner T.S., Kotloff K., Langley J.M., Wanke C., Warren C.A., Cheng A.C., et al. 2017 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea. Clin. Infect. Dis. 2017;65:1963–1973. doi: 10.1093/cid/cix959.
    1. Tunkel A.R., Hartman B.J., Kaplan S.L., Kaufman B.A., Roos K.L., Scheld W.M., Whitley R.J. Practice guidelines for the management of bacterial meningitis. Clin. Infect. Dis. 2004;39:1267–1284. doi: 10.1086/425368.
    1. Bookstaver P.B., Rokas K.E., Norris L.B., Edwards J.M., Sherertz R.J. Stability and compatibility of antimicrobial lock solutions. Am. J. Health Syst. Pharm. 2013;70:2185–2198. doi: 10.2146/ajhp120119.
    1. Tunkel A.R., Hasbun R., Bhimraj A., Byers K., Kaplan S.L., Michael Scheld W., van de Beek D., Bleck T.P., Garton H.J., Zunt J.R. 2017 Infectious Diseases Society of America’s Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis. Clin. Infect. Dis. 2017 doi: 10.1093/cid/cix152.
    1. Destache C.J., Guervil D.J., Kaye K.S. Ceftaroline fosamil for the treatment of Gram-positive endocarditis: CAPTURE study experience. Int. J. Antimicrob. Agents. 2019;53:644–649. doi: 10.1016/j.ijantimicag.2019.01.014.
    1. Zhanel G.G., Lam A., Schweizer F., Thomson K., Walkty A., Rubinstein E., Gin A.S., Hoban D.J., Noreddin A.M., Karlowsky J.A. Ceftobiprole: A review of a broad-spectrum and anti-MRSA cephalosporin. Am. J. Clin. Dermatol. 2008;9:245–254. doi: 10.2165/00128071-200809040-00004.
    1. Merck & Co., Inc. Zerbaxa® [Package Insert] Merck & Co., Inc.; Syracuse, NY, USA: 2018.
    1. [Internet] Bethesda (MD): National Library of Medicine (US). 2014 February 25. Identifier NCT02070757, Safety and Efficacy Study of Ceftolozane/Tazobactam to Treat Ventilated Nosocomial Pneumonia (MK-7625A-008) (ASPECT-NP); 2014 September 23. [(accessed on 17 May 2019)]; Available online: .
    1. Macy E. Penicillin and beta-lactam allergy: Epidemiology and diagnosis. Curr. Allergy Asthma Rep. 2014;14:476. doi: 10.1007/s11882-014-0476-y.
    1. Yoon S.Y., Park S.Y., Kim S., Lee T., Lee Y.S., Kwon H.S., Cho Y.S., Moon H.B., Kim T.B. Validation of the cephalosporin intradermal skin test for predicting immediate hypersensitivity: A prospective study with drug challenge. Allergy. 2013;68:938–944. doi: 10.1111/all.12182.
    1. Goodman E.J., Morgan M.J., Johnson P.A., Nichols B.A., Denk N., Gold B.B. Cephalosporins can be given to penicillin-allergic patients who do not exhibit an anaphylactic response. J. Clin. Anesth. 2001;13:561–564. doi: 10.1016/S0952-8180(01)00329-4.
    1. Anne S., Reisman R.E. Risk of administering cephalosporin antibiotics to patients with histories of penicillin allergy. Ann. Allergy Asthma Immunol. 1995;74:167–170.
    1. Romano A., Valluzzi R.L., Caruso C., Maggioletti M., Quaratino D., Gaeta F. Cross-Reactivity and Tolerability of Cephalosporins in Patients with IgE-Mediated Hypersensitivity to Penicillins. J. Allergy Clin. Immunol. Pract. 2018;6:1662–1672. doi: 10.1016/j.jaip.2018.01.020.
    1. Pichichero M.E., Casey J.R. Safe use of selected cephalosporins in penicillin-allergic patients: A meta-analysis. Otolaryngol. Head Neck Surg. 2007;136:340–347. doi: 10.1016/j.otohns.2006.10.007.
    1. Macy E., Contreras R. Adverse reactions associated with oral and parenteral use of cephalosporins: A retrospective population-based analysis. J. Allergy Clin. Immunol. 2015;135:745–752. doi: 10.1016/j.jaci.2014.07.062.
    1. Yang M.S., Kang D.Y., Seo B., Park H.J., Park S.Y., Kim M.Y., Park K.H., Koo S.M., Nam Y.H., Kim S., et al. Incidence of cephalosporin-induced anaphylaxis and clinical efficacy of screening intradermal tests with cephalosporins: A large multicenter retrospective cohort study. Allergy. 2018;73:1833–1841. doi: 10.1111/all.13435.
    1. Strom B.L., Schinnar R., Apter A.J., Margolis D.J., Lautenbach E., Hennessy S., Bilker W.B., Pettitt D. Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. N. Engl. J. Med. 2003;349:1628–1635. doi: 10.1056/NEJMoa022963.
    1. Fonacier L., Hirschberg R., Gerson S. Adverse drug reactions to a cephalosporins in hospitalized patients with a history of penicillin allergy. Allergy Asthma Proc. 2005;26:135–141.
    1. Pichichero M.E., Zagursky R. Penicillin and cephalosporin allergy. Ann. Allergy Asthma Immunol. 2014;112:404–412. doi: 10.1016/j.anai.2014.02.005.
    1. Terico A.T., Gallagher J.C. Beta-lactam hypersensitivity and cross-reactivity. J. Pharm. Pract. 2014;27:530–544. doi: 10.1177/0897190014546109.
    1. Barber M.S., Giesecke U., Reichert A., Minas W. Industrial enzymatic production of cephalosporin-based beta-lactams. Adv. Biochem. Eng. Biotechnol. 2004;88:179–215.
    1. Kim M.H., Lee J.M. Diagnosis and management of immediate hypersensitivity reactions to cephalosporins. Allergy Asthma Immunol. Res. 2014;6:485–495. doi: 10.4168/aair.2014.6.6.485.
    1. Madaan A., Li J.T. Cephalosporin allergy. Immunol. Allergy Clin. North Am. 2004;24:463–476. doi: 10.1016/j.iac.2004.03.009.
    1. Romano A., Gaeta F., Arribas Poves M.F., Valluzzi R.L. Cross-Reactivity among Beta-Lactams. Curr. Allergy Asthma Rep. 2016;16:24. doi: 10.1007/s11882-016-0594-9.
    1. Macy E., Blumenthal K.G. Are Cephalosporins Safe for Use in Penicillin Allergy without Prior Allergy Evaluation? J. Allergy Clin. Immunol. Pract. 2018;6:82–89. doi: 10.1016/j.jaip.2017.07.033.
    1. Sacco K.A., Cochran B.P., Epps K., Parkulo M., Gonzalez-Estrada A. Inpatient beta-lactam test-dose protocol and antimicrobial stewardship in patients with a history of penicillin allergy. Ann. Allergy Asthma Immunol. 2019;122:184–188. doi: 10.1016/j.anai.2018.11.008.
    1. Miranda A., Blanca M., Vega J.M., Moreno F., Carmona M.J., Garcia J.J., Segurado E., Justicia J.L., Juarez C. Cross-reactivity between a penicillin and a cephalosporin with the same side chain. J. Allergy Clin. Immunol. 1996;98:671–677. doi: 10.1016/S0091-6749(96)70101-X.
    1. Audicana M., Bernaola G., Urrutia I., Echechipia S., Gastaminza G., Munoz D., Fernandez E., Fernandez de Corres L. Allergic reactions to betalactams: Studies in a group of patients allergic to penicillin and evaluation of cross-reactivity with cephalosporin. Allergy. 1994;49:108–113. doi: 10.1111/j.1398-9995.1994.tb00809.x.
    1. Romano A., Gueant-Rodriguez R.M., Viola M., Pettinato R., Gueant J.L. Cross-reactivity and tolerability of cephalosporins in patients with immediate hypersensitivity to penicillins. Ann. Intern. Med. 2004;141:16–22. doi: 10.7326/0003-4819-141-1-200407060-00010.
    1. Blanca M., Fernandez J., Miranda A., Terrados S., Torres M.J., Vega J.M., Avila M.J., Perez E., Garcia J.J., Suau R. Cross-reactivity between penicillins and cephalosporins: Clinical and immunologic studies. J. Allergy Clin. Immunol. 1989;83:381–385. doi: 10.1016/0091-6749(89)90122-X.
    1. Novalbos A., Sastre J., Cuesta J., De Las Heras M., Lluch-Bernal M., Bombin C., Quirce S. Lack of allergic cross-reactivity to cephalosporins among patients allergic to penicillins. Clin. Exp. Allergy. 2001;31:438–443. doi: 10.1046/j.1365-2222.2001.00992.x.
    1. Uyttebroek A.P., Decuyper I.I., Bridts C.H., Romano A., Hagendorens M.M., Ebo D.G., Sabato V. Cefazolin Hypersensitivity: Toward Optimized Diagnosis. J. Allergy Clin. Immunol. Pract. 2016;4:1232–1236. doi: 10.1016/j.jaip.2016.05.011.
    1. Epstein R.H., Jacques P.S., Wanderer J.P., Bombulie M.R., Agarwalla N. Prophylactic Antibiotic Management of Surgical Patients Noted as “Allergic” to Penicillin at Two Academic Hospitals. A A Case Rep. 2016;6:263–267. doi: 10.1213/XAA.0000000000000253.
    1. Beltran R.J., Kako H., Chovanec T., Ramesh A., Bissonnette B., Tobias J.D. Penicillin allergy and surgical prophylaxis: Cephalosporin cross-reactivity risk in a pediatric tertiary care center. J. Pediatr. Surg. 2015;50:856–859. doi: 10.1016/j.jpedsurg.2014.10.048.
    1. MacPherson R.D., Willcox C., Chow C., Wang A. Anaesthetist’s responses to patients’ self-reported drug allergies. Br. J. Anaesth. 2006;97:634–639. doi: 10.1093/bja/ael237.
    1. Crotty D.J., Chen X.J., Scipione M.R., Dubrovskaya Y., Louie E., Ladapo J.A., Papadopoulos J. Allergic Reactions in Hospitalized Patients With a Self-Reported Penicillin Allergy Who Receive a Cephalosporin or Meropenem. J. Pharm. Pract. 2017;30:42–48. doi: 10.1177/0897190015587254.
    1. Romano A., Gaeta F., Valluzzi R.L., Maggioletti M., Zaffiro A., Caruso C., Quaratino D. IgE-mediated hypersensitivity to cephalosporins: Cross-reactivity and tolerability of alternative cephalosporins. J. Allergy Clin. Immunol. 2015;136:685–691. doi: 10.1016/j.jaci.2015.03.012.
    1. Antunez C., Blanca-Lopez N., Torres M.J., Mayorga C., Perez-Inestrosa E., Montanez M.I., Fernandez T., Blanca M. Immediate allergic reactions to cephalosporins: Evaluation of cross-reactivity with a panel of penicillins and cephalosporins. J. Allergy Clin. Immunol. 2006;117:404–410. doi: 10.1016/j.jaci.2005.10.032.
    1. Gueant J.L., Gueant-Rodriguez R.M., Viola M., Valluzzi R.L., Romano A. IgE-mediated hypersensitivity to cephalosporins. Curr. Pharm. Des. 2006;12:3335–3345. doi: 10.2174/138161206778194060.
    1. Moss R.B. Sensitization to aztreonam and cross-reactivity with other beta-lactam antibiotics in high-risk patients with cystic fibrosis. J. Allergy Clin. Immunol. 1991;87:78–88. doi: 10.1016/0091-6749(91)90215-A.
    1. Kula B., Djordjevic G., Robinson J.L. A systematic review: Can one prescribe carbapenems to patients with IgE-mediated allergy to penicillins or cephalosporins? Clin. Infect. Dis. 2014;59:1113–1122. doi: 10.1093/cid/ciu587.
    1. Dias de Castro E., Leblanc A., Sarmento A., Cernadas J.R. An unusual case of delayed-type hypersensitivity to ceftriaxone and meropenem. Eur. Ann. Allergy Clin. Immunol. 2015;47:225–227.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit